Assembly Biosciences financials
$23.48−0.55%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.4M | $8.2M | $42.5M | $10.8M | $9.6M | $9.4M | $7.4M | $6.8M | $8.5M | $5.8M | $7.2M | $0.00 |
| Gross profit | $13.4M | $8.2M | $42.5M | $10.8M | $9.6M | $9.4M | $7.4M | $6.8M | $8.5M | $5.8M | $7.2M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$6.3M | -$11.4M | $19.8M | -$10.9M | -$11.1M | -$9.9M | -$11.5M | -$11.0M | -$12.2M | -$10.7M | -$12.6M | -$15.0M |
| Net income | -$3.9M | -$9.1M | $22.1M | -$9.2M | -$10.2M | -$8.8M | -$10.3M | -$9.6M | -$11.2M | -$9.1M | -$11.0M | -$14.4M |
| Net margin | −28.8% | −110.5% | 52.0% | −85.2% | −105.9% | −93.6% | −140.5% | −140.4% | −130.7% | −156.9% | −153.0% | — |
| Diluted EPS | $-0.20 | $-0.54 | $1.30 | $-0.72 | $-1.33 | $-1.17 | $-1.58 | $-1.51 | $-1.98 | $-1.66 | $-2.06 | $-3.29 |
| EBITDA | -$6.3M | -$11.3M | $19.8M | -$10.9M | -$11.1M | -$9.9M | -$11.5M | -$10.9M | -$12.2M | -$10.7M | -$12.5M | -$14.9M |
| Operating cash flow | -$15.5M | -$22.1M | $14.2M | -$15.1M | -$16.8M | -$23.4M | -$407.0K | -$15.2M | -$17.1M | -$18.4M | $73.6M | -$13.8M |
| Free cash flow | -$15.5M | -$22.1M | $14.2M | -$15.2M | -$16.8M | -$23.4M | -$407.0K | -$15.2M | -$17.1M | -$18.4M | $73.6M | -$14.0M |
| Diluted shares | 18.9M | 16.9M | 17.0M | 12.7M | 7.7M | 7.5M | 6.5M | 6.4M | 5.6M | 5.5M | 5.3M | 4.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.3M | $31.1M | $58.5M | $22.5M | $24.0M | $23.4M |
| Short-term investments | $288.1M | $195.5M | $189.7M | $210.0M | $51.0M | $67.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $330.8M | $235.5M | $257.6M | $240.0M | $80.8M | $99.0M |
| Total liabilities | $25.2M | $36.9M | $50.8M | $57.3M | $62.7M | $71.9M |
| Shareholders' equity | $305.6M | $198.6M | $206.8M | $182.7M | $18.1M | $27.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology